World's Best Scientists 2026 revealed!

D-Index & Metrics

Genetics

D-Index
73
Citations
19139
World Ranking
2045
National Ranking
934

Medicine

D-Index
74
Citations
19296
World Ranking
19422
National Ranking
9674

Harry A. Drabkin publication distribution in Genetics in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Genetics in 2026. The highlighted bar marks where Harry A. Drabkin sits on this spectrum.

45–54 publications: 6 scientists 55–64 publications: 10 scientists 65–74 publications: 35 scientists 75–84 publications: 84 scientists 85–94 publications: 102 scientists 95–104 publications: 151 scientists 105–114 publications: 175 scientists 115–124 publications: 203 scientists 125–134 publications: 217 scientists 135–144 publications: 205 scientists 145–154 publications: 193 scientists 155–164 publications: 188 scientists 165–174 publications: 170 scientists 175–184 publications: 178 scientists 185–194 publications: 164 scientists 195–204 publications: 173 scientists 205–214 publications: 159 scientists 215–224 publications: 134 scientists 225–234 publications: 143 scientists 235–244 publications: 105 scientists 245–254 publications: 114 scientists 255–264 publications: 92 scientists 265–274 publications: 88 scientists 275–284 publications: 87 scientists 285–294 publications: 80 scientists 295–304 publications: 62 scientists 305–314 publications: 75 scientists 315–324 publications: 67 scientists 325–334 publications: 60 scientists 335–344 publications: 52 scientists 345–354 publications: 40 scientists 355–364 publications: 48 scientists 365–374 publications: 47 scientists 375–384 publications: 46 scientists 385–394 publications: 31 scientists 395–404 publications: 27 scientists 405–414 publications: 40 scientists 415–424 publications: 30 scientists 425–434 publications: 43 scientists 435–444 publications: 29 scientists 445–454 publications: 14 scientists 455–464 publications: 28 scientists 465–474 publications: 21 scientists 475–484 publications: 21 scientists 485–494 publications: 22 scientists 495–504 publications: 17 scientists 505–514 publications: 12 scientists 515–524 publications: 11 scientists 525–534 publications: 8 scientists 535–544 publications: 8 scientists 545–554 publications: 14 scientists 555–564 publications: 4 scientists 565–574 publications: 11 scientists 575–584 publications: 5 scientists 585–594 publications: 11 scientists 595–604 publications: 12 scientists 605–614 publications: 7 scientists 615–624 publications: 6 scientists 625–634 publications: 10 scientists 635–644 publications: 9 scientists 645–654 publications: 10 scientists 655–664 publications: 6 scientists 665–674 publications: 6 scientists 675–684 publications: 6 scientists 685–694 publications: 4 scientists 695–702 publications: 6 scientists 703+ publications: 100 scientists
45 publications 703+

This scientist: 246 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 703 publications or more.

Harry A. Drabkin D-index placement in Genetics in 2026

The chart shows the D-index (discipline H-index) distribution of Genetics scientists ranked by Research.com in 2026. The highlighted bar marks where Harry A. Drabkin sits on this spectrum.

40–41 D-Index: 24 scientists 42–43 D-Index: 52 scientists 44–45 D-Index: 84 scientists 46–47 D-Index: 112 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 141 scientists 52–53 D-Index: 143 scientists 54–55 D-Index: 145 scientists 56–57 D-Index: 179 scientists 58–59 D-Index: 162 scientists 60–61 D-Index: 175 scientists 62–63 D-Index: 191 scientists 64–65 D-Index: 172 scientists 66–67 D-Index: 184 scientists 68–69 D-Index: 164 scientists 70–71 D-Index: 158 scientists 72–73 D-Index: 150 scientists 74–75 D-Index: 136 scientists 76–77 D-Index: 127 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 111 scientists 82–83 D-Index: 110 scientists 84–85 D-Index: 110 scientists 86–87 D-Index: 84 scientists 88–89 D-Index: 102 scientists 90–91 D-Index: 66 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 70 scientists 96–97 D-Index: 54 scientists 98–99 D-Index: 60 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 55 scientists 104–105 D-Index: 45 scientists 106–107 D-Index: 42 scientists 108–109 D-Index: 28 scientists 110–111 D-Index: 39 scientists 112–113 D-Index: 25 scientists 114–115 D-Index: 31 scientists 116–117 D-Index: 29 scientists 118–119 D-Index: 34 scientists 120–121 D-Index: 29 scientists 122–123 D-Index: 29 scientists 124–125 D-Index: 18 scientists 126–127 D-Index: 27 scientists 128–129 D-Index: 22 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 11 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 12 scientists 138–139 D-Index: 21 scientists 140–141 D-Index: 4 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 14 scientists 146–147 D-Index: 6 scientists 148–149 D-Index: 10 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 9 scientists 154–155 D-Index: 8 scientists 156–157 D-Index: 8 scientists 158–159 D-Index: 9 scientists 160+ D-Index: 96 scientists
40 D-Index 160+

This scientist: 73 D-Index — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 160 D-Index or more.

Overview

Harry A. Drabkin is affiliated with the Medical University of South Carolina in the United States. Their research primarily focuses on the fields of Biochemistry, Genetics and Molecular Biology, and Medicine, with specific contributions in Molecular Biology, Oncology, and Cancer Research.

The main topics explored in their work include:

  • Angiogenesis and VEGF in Cancer
  • Cancer Cells and Metastasis
  • Lymphatic System and Diseases
  • Cancer, Hypoxia, and Metabolism
  • Glycosylation and Glycoproteins Research

Drabkin has contributed to recent scientific literature with notable papers such as:

  • Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer, published in 2020 in the Journal of Thoracic and Cardiovascular Surgery
  • Abstract 2994: Inhibition of the NRP2b:GSK3β binding interaction with peptides and macrocycles exerts anticancer effects in lung cancer, published in 2020 in Cancer Research

Their frequent co-authors include:

  • Anastasios Dimou
  • Cécile Nasarre
  • Yuri K. Peterson
  • Patrick Nasarre
  • Kent Armeson

Publications have appeared in venues such as the Journal of Thoracic and Cardiovascular Surgery and Cancer Research, reflecting the intersection of Drabkin's molecular biology expertise with cancer-related investigations.

Best Publications

  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Bruce G. Redman

  • Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion

    Gilles David;Nacer Abbas;Giovanni Stevanin;Alexandra Dürr

  • Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma

    B. R. Seizinger;G. A. Rouleau;L. J. Ozelius;A. H. Lane

  • Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt.

    P Erickson;J Gao;KS Chang;T Look

  • Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

    Samir E. Witta;Robert M. Gemmill;Fred R. Hirsch;Christopher D. Coldren

  • High-Throughput Tissue Microarray Analysis Used to Evaluate Biology and Prognostic Significance of the E-Cadherin Pathway in Non–Small-Cell Lung Cancer

    Roy M. Bremnes;R. Veve;E. Gabrielson;F. R. Hirsch

  • Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer

    Ronald M. Bukowski;Fairooz F. Kabbinavar;Robert A. Figlin;Keith Flaherty

  • Unified nomenclature for the semaphorins/collapsins [1]

    J. A. Bamberg;S. Baumgartner;H. Betz;J. Bolz

  • A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.

    Jonathan E. Rosenberg;Jonathan E. Rosenberg;Richard M. Bambury;Eliezer M. Van Allen;Eliezer M. Van Allen;Harry A. Drabkin

  • Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer

    Mariam Dohadwala;Seok-Chul Yang;Jie Luo;Sherven Sharma

  • Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B

    Yoshio Tomizawa;Yoshitaka Sekido;Yoshitaka Sekido;Masashi Kondo;Boning Gao

  • Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

    Walter M. Stadler;Robert A. Figlin;David F. McDermott;Janice P. Dutcher

  • Altered hox and wnt7a expression in human lung cancer

    Harry A. Drabkin;Robert M. Gemmill

  • Angiogenic Squamous Dysplasia in Bronchi of Individuals at High Risk for Lung Cancer

    Robert L. Keith;York E. Miller;Robert M. Gemmill;Harry A. Drabkin

  • Detection of DNA Rearrangements in the AML1 and ETO Loci and of an AML1/ETO Fusion mRNA in Patients With t(8;21) Acute Myeloid Leukemia

    Giuseppina Nucifora;Debra J. Birn;Paul Erickson;Jizong Gao

  • Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation.

    Cristina G. de Guzman;Alan J. Warren;Zheng Zhang;Larry Gartland

  • Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin.

    Roche J;Boldog F;Robinson M;Robinson L

  • An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation

    J. R. Downing;D. R. Head;A. M. Curcio-Brint;M. G. Hulshof

  • Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia.

    H A Drabkin;C Parsy;K Ferguson;F Guilhot

  • The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1

    Giuseppina Nucifora;Catherine R. Begy;Paul Erickson;Harry A. Drabkin

Frequent Co-Authors

Robert M. Gemmill
Robert M. Gemmill Medical University of South Carolina
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Wilbur A. Franklin
Wilbur A. Franklin University of Colorado Denver
Anna E. Barón
Anna E. Barón University of Colorado Anschutz Medical Campus
Ronald M. Bukowski
Ronald M. Bukowski Cleveland Clinic
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
Jan Trka
Jan Trka Charles University
Elisabeth Brambilla
Elisabeth Brambilla Grenoble Alpes University
Charles H.C.M. Buys
Charles H.C.M. Buys University of Groningen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Genetics opens doors to diverse and rewarding fields. Many students interested in genetics also explore health and life sciences, especially advanced nursing and clinical roles. With the growing demand for skilled healthcare professionals, online programs are increasingly popular due to their flexibility and affordability.

For those aiming to advance quickly in nursing, there are options such as the rn to bsn online cheap and fast programs. These pathways allow registered nurses to obtain their Bachelor of Science in Nursing efficiently and affordably. If you aspire to further your clinical practice, consider the online dnp fnp programs, which lead to advanced practitioner roles such as Family Nurse Practitioners.

Searching for the cheapest np school or the most affordable online nursing programs can significantly reduce your financial burden. Affordable online options make it easier to gain the qualifications needed for in-demand healthcare careers without leaving your job or relocating. These pathways provide a bridge between genetic science studies and practical, impactful medical careers.

Best Scientists Citing Harry A. Drabkin

Trending Scientists